Biologic Therapeutic Drugs Technology Analysis and Global Market Forecast Report 2024-2025 & 2029 Featuring Key Players - Merck, F. Hoffmann-La Roche, Johnson & Johnson, Pfizer, & Bristol-Myers Squibb
DUBLIN--(BUSINESS WIRE)--Jun 11, 2025--
The 'Biologic Therapeutic Drugs: Technologies and Global Markets' report has been added to ResearchAndMarkets.com's offering.
The global market for biologic therapeutic drugs is estimated to increase from $499.2 billion in 2024 to reach $794.5 billion by 2029, at a compound annual growth rate (CAGR) of 9.7% from 2024 through 2029.
This report provides an overview of the global biologic therapeutic drug market and analyzes market trends. It includes global revenue ($U.S. millions) for base year data for 2023 and estimated data for 2024. The forecast period is 2024 through 2029.
The pharmaceutical industry is undergoing tremendous transformations by focusing more on targeted and personalized therapies. The industry is witnessing a shift from traditional synthetic drugs to biologic therapeutic drugs, which are more efficacious, have better patient outcomes and improve quality of life. Biologic drugs are primarily classified into monoclonal antibodies; vaccines; peptide hormones; cell and gene therapies; and others, which include protein therapeutics (e.g., cytokines, enzymes, blood factors, fusion proteins) and other drugs (e.g., RNA-based therapies).
The biopharmaceutical industry has recently been witnessing tremendous growth due to the increasing demand for innovative therapies, such as monoclonal antibodies, cell and gene therapies and vaccines. The demand for these therapies is primarily driven by such factors as the increasing prevalence of chronic diseases, rising healthcare expenditures, increasing awareness, novel product launches and strong pipelines. The biologic approvals by the U.S. Food and Drug Administration (FDA) are increasing year on year, and 2023 was marked by the approval of two breakthrough therapies: the gene editing therapy Casgevy from Vertex Pharmaceutical and Leqembi (lecanemab) from Eisai Inc.
The entry of biosimilars into the market is expected to erode the revenues of the current branded products upon patent expiry. The complex manufacturing process, a lack of skilled workforce and high development costs translate to a high cost of therapy, which acts as a major barrier to the market.
The report focuses on the significant driving trends and challenges that affect the market and vendor landscape. It analyzes corporate environmental, social and governance (ESG) developments and discusses emerging technologies related to the market. The report concludes with an analysis of the competitive landscape, which provides the ranking and share of key players in the global biologic therapeutic drug market. It also has a section dedicated to company profiles that covers such details as overview, key financials, product portfolio and recent developments of key market players.
The report includes:
Company Profiles
Key Attributes:
Key Topics Covered:
Chapter 1 Executive Summary
Chapter 2 Market Overview
Chapter 3 Market Dynamics
Chapter 4 Regulatory Landscape
Chapter 5 Emerging Technologies and Developments
Chapter 6 Market Segmentation Analysis
Chapter 7 Competitive Intelligence
Chapter 8 Sustainability in Biologics Therapeutic Drug Market: An ESG Perspective
Chapter 9 Appendix
For more information about this report visit https://www.researchandmarkets.com/r/lsetb6
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250611945349/en/
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD:
INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH TECHNOLOGY PHARMACEUTICAL HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2025.
PUB: 06/11/2025 08:33 AM/DISC: 06/11/2025 08:32 AM
http://www.businesswire.com/news/home/20250611945349/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
Plans unveiled for NHS funding to be linked to patient feedback
NHS funding could be linked to patient feedback under new plans, with poorly performing services that "don't listen" penalised with less money. As part of the "10 Year Health Plan" to be unveiled next week, a new scheme will be trialled that will see patients asked to rate the service they received - and if they feel it should get a funding boost or not. It will be introduced first for services that have a track record of very poor performance and where there is evidence of patients "not being listened to", the government said. This will create a "powerful incentive for services to listen to feedback and improve patients' experience", it added. Sky News understands that it will not mean bonuses or pay increases for the best performing staff. NHS payment mechanisms will also be reformed to reward services that keep patients out of hospital as part of a new 'Year of Care Payments' initiative and the government's wider plan for change. Speaking to The Times, chief executive of the NHS Confederation Matthew Taylor expressed concerns about the trial. He told the newspaper: "Patient experience is determined by far more than their individual interaction with the clinician and so, unless this is very carefully designed and evaluated, there is a risk that providers could be penalised for more systemic issues, such as constraints around staffing or estates, that are beyond their immediate control to fix." He said that NHS leaders would be keen to "understand more about the proposal", because elements were "concerning". Read more from Sky News Health Secretary Wes Streeting said: "We will reward great patient care, so patient experience and clinical excellence are met with extra cash. These reforms are key to keeping people healthy and out of hospital, and to making the NHS sustainable for the long-term as part of the Plan for Change." In the raft of announcements in the 10 Year Health Plan, the government has said 201 bodies responsible for overseeing and running parts of the NHS in England will be scrapped. These include Healthwatch England, set up in 2012 to speak out on behalf of NHS and social care patients, the National Guardian's Office, created in 2015 to support NHS whistleblowers, and the Health Services Safety Investigations Body (HSSIB). Elsewhere, the new head of NHS England Sir Jim Mackey said key parts of the NHS appear "built to keep the public away because it's an inconvenience". "We've made it really hard, and we've probably all been on the end of it," he told the Daily Telegraph. "The ward clerk only works nine to five, or they're busy doing other stuff; the GP practice scrambles every morning."
Yahoo
17 minutes ago
- Yahoo
Provexis (LON:PXS) Is In A Strong Position To Grow Its Business
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed. Given this risk, we thought we'd take a look at whether Provexis (LON:PXS) shareholders should be worried about its cash burn. For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth (also called its negative free cash flow). We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. You can calculate a company's cash runway by dividing the amount of cash it has by the rate at which it is spending that cash. In September 2024, Provexis had UK£478k in cash, and was debt-free. Looking at the last year, the company burnt through UK£113k. So it had a cash runway of about 4.2 years from September 2024. A runway of this length affords the company the time and space it needs to develop the business. The image below shows how its cash balance has been changing over the last few years. See our latest analysis for Provexis Although Provexis had revenue of UK£1.2m in the last twelve months, its operating revenue was only UK£1.2m in that time period. We don't think that's enough operating revenue for us to understand too much from revenue growth rates, since the company is growing off a low base. So we'll focus on the cash burn, today. Notably, its cash burn was actually down by 74% in the last year, which is a real positive in terms of resilience, but uninspiring when it comes to investment for growth. Of course, we've only taken a quick look at the stock's growth metrics, here. This graph of historic revenue growth shows how Provexis is building its business over time. There's no doubt Provexis' rapidly reducing cash burn brings comfort, but even if it's only hypothetical, it's always worth asking how easily it could raise more money to fund further growth. Companies can raise capital through either debt or equity. Commonly, a business will sell new shares in itself to raise cash and drive growth. By comparing a company's annual cash burn to its total market capitalisation, we can estimate roughly how many shares it would have to issue in order to run the company for another year (at the same burn rate). Since it has a market capitalisation of UK£16m, Provexis' UK£113k in cash burn equates to about 0.7% of its market value. So it could almost certainly just borrow a little to fund another year's growth, or else easily raise the cash by issuing a few shares. As you can probably tell by now, we're not too worried about Provexis' cash burn. For example, we think its cash runway suggests that the company is on a good path. But it's fair to say that its cash burn reduction was also very reassuring. Looking at all the measures in this article, together, we're not worried about its rate of cash burn, which seems to be under control. Taking a deeper dive, we've spotted 4 warning signs for Provexis you should be aware of, and 1 of them is a bit concerning. If you would prefer to check out another company with better fundamentals, then do not miss this free list of interesting companies, that have HIGH return on equity and low debt or this list of stocks which are all forecast to grow. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
22 minutes ago
- Yahoo
D-Wave's Advantage2 Gains Traction: More Upside Ahead for QBTS Stock?
D-Wave Quantum's QBTS standout growth catalyst this quarter is the successful launch and commercial deployment of its next-generation Advantage2 quantum annealer. In the last-reported quarter, the company posted 509% year-over-year growth in revenues, driven mainly by the first Advantage2 sale to the Julich Supercomputing Center. Now generally available via D-Wave Quantum's Leap cloud, it's gaining traction in real-world applications, from U.S. defense to AI-driven drug discovery. Shares of D-Wave Quantum have soared 67.4% over the past three months, largely outperforming the broader industry, sector and the benchmark. Image Source: Zacks Investment Research Commercialization of the Advantage2 Quantum System A major driver of D-Wave Quantum's record first-quarter 2025 performance is the rapid commercialization of its next-gen Advantage2 quantum system. Featuring over 4,400 qubits, the platform delivers significant performance gains, 2x coherence time, 40% higher energy scale, and enhanced qubit connectivity, enabling more complex real-world optimization in AI, logistics, finance and materials science. The system's first commercial sale to Julich Supercomputing Center contributed heavily to the first quarter in revenues. A second deployment is underway at Davidson Technologies for U.S. defense applications, highlighting Advantage2's expanding relevance in government sectors. Following its general availability in May 2025 via the Leap cloud, D-Wave introduced new hybrid solvers for both continuous and integer variables, broadening the scope of use cases to include budgeting, scheduling and resource optimization. Beyond hardware, D-Wave also launched a quantum AI toolkit integrated with PyTorch, positioning Advantage2 as a platform for innovation in machine learning. IonQ IONQ: It is rapidly scaling up through major moves, including its $1.075 billion acquisition of Oxford Ionics to accelerate fault-tolerant quantum development. It also launched a quantum networking hub via a $22 million Forte Enterprise deal with EPB and acquired Lightsynq and Capella Space to support its quantum internet vision. On the application side, IonQ partnered with AstraZeneca, AWS and NVIDIA NVDA to achieve a 20× speedup in simulating a pharmaceutical reaction, showcasing growing real-world impact. Rigetti Computing RGTI: It has emphasized improvements in qubit fidelity and error mitigation, partnered with government entities for testing and calibration of its superconducting processors, and is reportedly advancing its roadmap toward hybrid quantum-classical cloud services. Although not yet celebrated through headline-making releases, Rigetti is positioning itself as a 'complete-stack' provider, integrating software infrastructure like its Quil programming framework and Forest SDK to support developer adoption alongside its next-gen hardware. The Zacks Consensus Estimate for QBTS' 2025 earnings implies a 72% improvement over 2024. Image Source: Zacks Investment Research D-Wave Quantum currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report NVIDIA Corporation (NVDA) : Free Stock Analysis Report IonQ, Inc. (IONQ) : Free Stock Analysis Report Rigetti Computing, Inc. (RGTI) : Free Stock Analysis Report D-Wave Quantum Inc. (QBTS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
